Useful in weakness, weight loss and stress conditions
Discussion GLP-1RA is a new type of hypoglycemic drug used in the treatment of T2DM, which is widely used in clinical practice at home and abroad due to its reliable and safe efficacy [23,24,25]
NICE first recommended the drug in draft guidance 2022, after a clinical trial of just under 2000 volunteers found that people lost on average 12% more weight with semaglutide alongside supervised weight loss coaching (BMJ 2023;380:556)
1% reported fainting, headache, and insomnia
The most effective approach addresses both
The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment